A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Multiple Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.

Trial Profile

A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Multiple Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs RO 5545965 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 17 Feb 2014 Status has gone changed from active not recruiting to completed, according to ClinicalTrials.gov record.
    • 23 Jan 2014 Planned number of patients changed from 40 to 44 as reported by ClinicalTrials.gov record.
    • 09 Dec 2013 Planned end date changed from 1 Nov 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top